Skip to content
UpLiftRx
MedicationsLabsProvidersVisitsOrdersDashboardSign in
UpLiftRx
MedicationsLabsProvidersVisitsOrdersDashboard
Sign in
Transparency
  • Company
  • Our clinicians
  • Pharmacy partners
  • Where we operate
  • Accreditation
Legal
  • Terms of Service
  • Privacy Policy
  • Notice of Privacy Practices
  • Telehealth Consent
  • Auto-Renewal Terms
  • Refund & Shipping
  • Pharmacy Disclosure
  • Prescribing Policy
  • Patient Rights & Nondiscrimination
  • Texas Medical Board Complaint Notice
  • SMS Terms
  • Cookies
  • California Privacy
  • Accessibility
Support
  • support@upliftrx.co
  • Member sign in

Medical emergency? Call 911. In crisis? Call or text 988 (Suicide & Crisis Lifeline). UpLiftRX is not for emergencies.

Prescription products require an online consultation with an independent, licensed clinician, who decides whether treatment is appropriate. Available to adults 18+ in states where our clinicians are licensed.

Compounded medications are prepared by state-licensed pharmacies for an individual patient and are not FDA-approved. FDA does not review compounded drugs for safety, effectiveness, or quality before they are dispensed.

Latitude Investments Management Ltd. Liability Co. d/b/a UpLiftRX provides a technology platform and is not a pharmacy or a medical provider. Medical services are provided by independent, licensed clinicians of a professional medical group (being finalized). Prescriptions are dispensed by independent, state-licensed pharmacies. Latitude Investments Management Ltd. Liability Co., a Wyoming limited liability company (filing no. 2024-001499647), 5709 Gardendale Dr, STE D, Houston, TX 77092.

Wegovy® and Saxenda® are registered trademarks of Novo Nordisk A/S. Zepbound® and Cialis® are registered trademarks of Eli Lilly and Company. Contrave® is a registered trademark of Currax Pharmaceuticals LLC. Viagra® is a registered trademark of Viatris Specialty LLC. All trademarks are the property of their respective owners. UpLiftRX is not affiliated with or endorsed by any drug manufacturer, and generic medications are not the brand-name products.

© 2026 Latitude Investments Management Ltd. Liability Co. d/b/a UpLiftRX.
  1. Home/
  2. Medications/
  3. Appetite Suppressant/
  4. Saxenda® (liraglutide)
Saxenda® (liraglutide) injectable, brand-name prescription medication, pharmacy prescription bag illustrationBrand-name · FDA-approved
Appetite Suppressant

Saxenda® (liraglutide) Multi-dose pen

Multi-dose pen

FDA-approved once-daily GLP-1 injection for chronic weight management in adults and adolescents 12 and older.

$129/ month· clinician care · medication billed by the pharmacy via insurance or manufacturer self-pay
Specification
Just this one: start consultation

Add several treatments and check out once. $0 today; each is charged only if prescribed.

Rx only · adults 18+. Requires an online consultation with an independent, licensed clinician, who decides whether treatment is appropriate. FDA-approved brand-name product; dispensed in manufacturer packaging by a licensed pharmacy.

Safety: GLP-1 receptor agonists caused thyroid C-cell tumors in rodents. Important safety information

Know before you start

How Saxenda® (liraglutide) treatment works

How it works

GLP-1 (and dual/triple agonist) medications mimic gut hormones that regulate appetite and blood sugar. They slow stomach emptying and act on appetite centers in the brain, helping you feel full sooner and stay full longer — so sustainable calorie reduction stops being a willpower fight.

What to expect

  • Weeks 1–4: dose titration begins low to minimize nausea; appetite typically quiets noticeably.
  • Months 2–3: dose adjusts based on response and tolerance at your check-ins.
  • Ongoing: monthly shipments, message your care team anytime, labs as clinically indicated.

Common side effects

  • Nausea (most common, usually improves after the first weeks)
  • Constipation or diarrhea
  • Fatigue or headache during titration
  • Injection-site irritation

Safety & who it's not for

Not for patients with a personal/family history of medullary thyroid carcinoma or MEN 2, a history of pancreatitis, or who are pregnant, breastfeeding, or trying to conceive. Your clinician screens for these and more during intake.

Saxenda® (liraglutide) FAQ

What is Saxenda® (liraglutide)?

FDA-approved once-daily GLP-1 injection for chronic weight management in adults and adolescents 12 and older.

What does the research say about Liraglutide?

PubMed indexes 5,684 publications that mention Liraglutide, including 969 randomized trials, systematic reviews, or meta-analyses. ClinicalTrials.gov lists 515 registered studies. The sources are linked on this page.

Do I need to diet and exercise too?

These medications work best alongside basic nutrition and activity habits. Your clinician will set realistic expectations — most members find the medication makes those habits dramatically easier to keep.

Is compounded medication the same as the brand?

Compounded drugs are not FDA-approved and are not generic or automatically equivalent to an approved product. When compounding is clinically appropriate and legally available, the exact ingredient form, concentration, route, source, and dispensing facility must be independently verified.

What happens if I stop?

Appetite typically returns toward baseline. Many members taper with their clinician's guidance and keep results with maintenance habits; others stay on a maintenance dose.

Important safety information

Boxed warning: Risk of thyroid C-cell tumors

GLP-1 receptor agonists caused thyroid C-cell tumors in rodents. Their relevance to humans is unclear. Do not use if you or a family member have a history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN 2). Tell your clinician about any neck lump, hoarseness, trouble swallowing, or shortness of breath.

Tell your clinician about all medications and supplements you take. Seek emergency care (call 911) for severe reactions. Report side effects to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Saxenda® is a registered trademark of its owner. UpLiftRX is not affiliated with or endorsed by the manufacturer. Read the full Prescribing Information and Medication Guide from the manufacturer.

Similar products

Similar to Saxenda® (liraglutide)

See all in Appetite Suppressant →
Wegovy® (semaglutide) injectable, brand-name prescription medication, pharmacy prescription bag illustrationBrand-name · FDA-approved
Appetite Suppressant
Wegovy® (semaglutide)
5 options
Zepbound® (tirzepatide) injectable, brand-name prescription medication, pharmacy prescription bag illustrationBrand-name · FDA-approved
Appetite Suppressant
Zepbound® (tirzepatide)
6 options
Contrave® (naltrexone/bupropion ER) oral, brand-name prescription medication, pharmacy prescription bag illustrationBrand-name · FDA-approved
Appetite Suppressant
Contrave® (naltrexone/bupropion ER)
8mg/90mg
Orforglipron + Pyridoxine (B6) oral, compounded prescription medication, UpLiftRX packagingCompounded · Not FDA-approved
Appetite Suppressant
Orforglipron + Pyridoxine (B6)
6 options
$129/mo
On this pageOverviewStrengths & pricesHow it's takenStorage & shippingResearch & sourcesFAQReviewsSafety
At a glance

What is Saxenda® (liraglutide) Multi-dose pen?

Saxenda® (liraglutide) is an FDA-approved brand-name prescription medication, dispensed by a licensed pharmacy in the manufacturer's packaging.

Form
Multi-dose pen
Active ingredients
Liraglutide
Options
1 strength and size option
Price
Clinician care from the program price; medication billed by the pharmacy
Prescription
Required. A licensed clinician decides whether it is appropriate.
FDA status
FDA-approved brand-name product, dispensed in the manufacturer's packaging
Dispensed by
A licensed pharmacy
Availability
In stock at one or more pharmacies

Product details from our pharmacy network's catalog, updated October 22, 2026.

Strengths & prices

Saxenda® (liraglutide) Multi-dose pen strengths and prices

1 option. Prices are per month and include the online visit, the medication, and shipping; you are charged only if a clinician prescribes it.
StrengthSizePriceAvailability
18mg/3mL (0.6–3mg daily)5 pens (90mg total)—In stock
Clinical research & sources

Research on the ingredients in Saxenda® (liraglutide) Multi-dose pen

Published research and public drug references for each active ingredient, from the U.S. National Library of Medicine (PubMed, MedlinePlus, DailyMed, RxNorm, PubChem), ClinicalTrials.gov, and FDA. Individual results vary.

Liraglutide

FDA status: FDA has approved products that contain liraglutide, including Saxenda, Victoza, Xultophy 100/3.6.

PubMed: 5,684 publications mention Liraglutide, 969 of them trials or reviews. Search PubMed

  1. Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis. Karakasis P et al. Metabolism: clinical and experimental, 2025. Network Meta-Analysis, Systematic Review. PMID 39719170 · DOI
  2. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. Rubino DM et al. JAMA, 2022. Clinical Trial, Phase III, Randomized Controlled Trial. PMID 35015037 · DOI
  3. Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis. Souza M et al. Hepatology (Baltimore, Md.), 2025. Systematic Review, Network Meta-Analysis. PMID 39903735 · DOI
  4. Liraglutide for Children 6 to <12 Years of Age with Obesity - A Randomized Trial. Fox CK et al. The New England journal of medicine, 2025. Randomized Controlled Trial, Clinical Trial, Phase III. PMID 39258838 · DOI
  5. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. Marso SP et al. The New England journal of medicine, 2016. Randomized Controlled Trial. PMID 27295427 · DOI

ClinicalTrials.gov: 515 registered studies. See all studies

  • NCT03341429 Evaluation of Liraglutide 3.0mg in Patients With Poor Weight-loss and a Suboptimal Glucagon-like Peptide-1 Response (Phase 4), completed
  • NCT03260881 Liraglutide Effects on Epicardial Fat Inflammatory Genes (Phase 4), completed
  • NCT01715428 Liraglutide and Cardio-Metabolic Risk Markers, completed

MedlinePlus drug information ↗FDA label (DailyMed) ↗RxNorm 475968 ↗PubChem CID 16134956 ↗Wikipedia ↗

Sources checked October 22, 2026. Listing a study is not a claim that this product is safe or effective for you; a licensed clinician makes that decision.

Patient reviews

Reviews come only from patients who received Saxenda® (liraglutide) Multi-dose pen through UpLiftRX. Each is checked for privacy and safety before it's published; we never remove a review for being negative. Individual experiences vary, and reviews aren't medical advice.

No reviews yet. Patients who receive Saxenda® (liraglutide) Multi-dose pen through UpLiftRX can leave a review after delivery.

For patients who received Saxenda® (liraglutide) Multi-dose pen.